CB1 Signaling in Forebrain and Sympathetic Neurons Is a Key Determinant of Endocannabinoid Actions on Energy Balance

Cell Metabolism

Volumn 11, Issue 4, 2010, Pages 273-285

  Quarta, Carmelo ^a   Bellocchio, Luigi ^b,c   Mancini, Giacomo ^d   Mazza, Roberta ^a   Cervino, Cristina ^a   Braulke, Luzie J ^e   Fekete, Csaba ^f,g   Latorre, Rocco ^h   Nanni, Cristina ⁱ   Bucci, Marco ^a,j   Clemens, Laura E ^e   Heldmaier, Gerhard ^e   Watanabe, Masahiko ^k   Leste Lassere, Thierry ^b,c   Maitre, Marlène ^b,c   Tedesco, Laura ^l,m   Fanelli, Flaminia ^a   Reuss, Stefan ^d   Klaus, Susanne ⁿ   Srivastava, Raj Kamal ^d   Monory, Krisztina ^d   Valerio, Alessandra ^l,o   Grandis, Annamaria ^h   De Giorgio, Roberto ^h   Pasquali, Renato ^a   Nisoli, Enzo ^l,m   Cota, Daniela ^b,c   Lutz, Beat ^d   Marsicano, Giovanni ^b,c   Pagotto, Uberto ^a   more..

^a Department of Clinical Medicine   (Italy)

^b INSTITUT FRANÇOIS MAGENDIE   (France)

^c UNIVERSITÉ DE BORDEAUX   (France)

^d JOHANNES GUTENBERG UNIVERSITY   (Germany)

^e PHILIPPS UNIVERSITY MARBURG   (Germany)

^f INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^g Tupper Research Institute   (United States)

^h UNIVERSITY OF BOLOGNA   (Italy)

ⁱ UNIVERSITY OF BOLOGNA   (Italy)

^j UNIVERSITY OF TURKU   (Finland)

^k HOKKAIDO UNIVERSITY   (Japan)

^l Integrated Laboratories Network   (Italy)

^m ISTITUTO AUXOLOGICO ITALIANO   (Italy)

ⁿ GERMAN INSTITUTE OF HUMAN NUTRITION   (Germany)

^o UNIVERSITY OF BRESCIA   (Italy)

more..

Author keywords

HUMDISEASE; MOLNEURO

Indexed keywords

CANNABINOID 1 RECEPTOR; ENDOCANNABINOID;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENERGY ABSORPTION; ENERGY BALANCE; FOREBRAIN; LEAN BODY WEIGHT; LIPID OXIDATION; MALE; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; SYMPATHETIC NERVE CELL; SYMPATHETIC TONE; THERMOGENESIS;

ANALYSIS OF VARIANCE; ANIMALS; BODY TEMPERATURE; CITRATE (SI)-SYNTHASE; DNA, MITOCHONDRIAL; ENERGY METABOLISM; FLUORESCENT ANTIBODY TECHNIQUE; HYPERPHAGIA; IMMUNOBLOTTING; IN SITU HYBRIDIZATION; MICE; MICE, KNOCKOUT; MODELS, BIOLOGICAL; OBESITY; PROSENCEPHALON; RECEPTOR, CANNABINOID, CB1; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SYMPATHETIC NERVOUS SYSTEM; THERMOGENESIS; X-RAY MICROTOMOGRAPHY;

MUS;

EID: 77950199353     PISSN: 15504131     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cmet.2010.02.015     Document Type: Article

References (32)

1. Addy C., Wright H., Van Laere K., Gantz I., Erondu N., Musser B.J., Lu K., Yuan J., Sanabria-Bohórquez S.M., Stoch A., et al. The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake. Cell Metab. 7 (2008) 68-78
2. Akbas F., Gasteyger C., Sjödin A., Astrup A., and Larsen T.M. A critical review of the cannabinoid receptor as a drug target for obesity management. Obes. Rev. 10 (2009) 58-67
3. Casanova E., Fehsenfeld S., Mantamadiotis T., Lemberger T., Greiner E., Stewart A.F., and Schütz G. A CamKIIalpha iCre BAC allows brain-specific gene inactivation. Genesis 31 (2001) 37-42
4. Cota D., Marsicano G., Tschöp M., Grübler Y., Flachskamm C., Schubert M., Auer D., Yassouridis A., Thöne-Reineke C., Ortmann S., et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J. Clin. Invest. 112 (2003) 423-431
5. Cota D., Sandoval D.A., Olivieri M., Prodi E., D'Alessio D.A., Woods S.C., Seeley R.J., and Obici S. Food intake-independent effects of CB1 antagonism on glucose and lipid metabolism. Obesity (Silver Spring) 17 (2009) 1641-1645
6. Di Marzo V., Goparaju S.K., Wang L., Liu J., Bátkai S., Járai Z., Fezza F., Miura G.I., Palmiter R.D., Sugiura T., and Kunos G. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 410 (2001) 822-825
7. Fukudome Y., Ohno-Shosaku T., Matsui M., Omori Y., Fukaya M., Tsubokawa H., Taketo M.M., Watanabe M., Manabe T., and Kano M. Two distinct classes of muscarinic action on hippocampal inhibitory synapses: M2-mediated direct suppression and M1/M3-mediated indirect suppression through endocannabinoid signalling. Eur. J. Neurosci. 19 (2004) 2682-2692
8. Galiè M., Farace P., Nanni C., Spinelli A., Nicolato E., Boschi F., Magnani P., Trespidi S., Ambrosini V., Fanti S., et al. Epithelial and mesenchymal tumor compartments exhibit in vivo complementary patterns of vascular perfusion and glucose metabolism. Neoplasia 9 (2007) 900-908
9. Grill H.J., and Hayes M.R. The nucleus tractus solitarius: a portal for visceral afferent signal processing, energy status assessment and integration of their combined effects on food intake. Int. J. Obes. (Lond.) 33 Suppl 1 (2009) S11-S15
10. Grossi G., Bargossi A.M., Lucarelli C., Paradisi R., Sprovieri C., and Sprovieri G. Improvements in automated analysis of catecholamine and related metabolites in biological samples by column-switching high-performance liquid chromatography. J. Chromatogr. 22 (1991) 273-284
11. Herling A.W., Kilp S., Elvert R., Haschke G., and Kramer W. Increased energy expenditure contributes more to the body weight-reducing effect of rimonabant than reduced food intake in candy-fed wistar rats. Endocrinology 149 (2008) 2557-2566
12. Jbilo O., Ravinet-Trillou C., Arnone M., Buisson I., Bribes E., Péleraux A., Pénarier G., Soubrié P., Le Fur G., Galiègue S., and Casellas P. The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance. FASEB J. 19 (2005) 1567-1569
13. Kunos G., Osei-Hyiaman D., Liu J., Godlewski G., and Bátkai S. Endocannabinoids and the control of energy homeostasis. J. Biol. Chem. 283 (2008) 33021-33025
14. Kunos G., Osei-Hyiaman D., Bátkai S., Sharkey K.A., and Makriyannis A. Should peripheral CB(1) cannabinoid receptors be selectively targeted for therapeutic gain?. Trends Pharmacol. Sci. 30 (2009) 1-7
15. LoVerme J., Duranti A., Tontini A., Spadoni G., Mor M., Rivara S., Stella N., Xu C., Tarzia G., and Piomelli D. Synthesis and characterization of a peripherally restricted CB1 cannabinoid antagonist, URB447, that reduces feeding and body-weight gain in mice. Bioorg. Med. Chem. Lett. 19 (2009) 639-643
16. Makara J.K., Katona I., Nyíri G., Németh B., Ledent C., Watanabe M., de Vente J., Freund T.F., and Hájos N. Involvement of nitric oxide in depolarization-induced suppression of inhibition in hippocampal pyramidal cells during activation of cholinergic receptors. J. Neurosci. 27 (2007) 10211-10222
17. Marsicano G., and Lutz B. Expression of the cannabinoid receptor CB1 in distinct neuronal subpopulations in the adult mouse forebrain. Eur. J. Neurosci. 11 (1999) 4213-4225
18. Marsicano G., Wotjak C.T., Azad S.C., Bisogno T., Rammes G., Cascio M.G., Hermann H., Tang J., Hofmann C., Zieglgänsberger W., et al. The endogenous cannabinoid system controls extinction of aversive memories. Nature 418 (2002) 530-534
19. Marsicano G., Goodenough S., Monory K., Hermann H., Eder M., Cannich A., Azad S.C., Cascio M.G., Gutiérrez S.O., van der Stelt M., et al. CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science 302 (2003) 84-88
20. McElroy J., Sieracki C., and Chorvat R. Non-brain penetrant CB1 receptor antagonists as novel treatment of obesity and related metabolic disorders. Obesity (Silver Spring) 16 Suppl. 1 (2008) S47
21. Monory K., Massa F., Egertová M., Eder M., Blaudzun H., Westenbroek R., Kelsch W., Jacob W., Marsch R., Ekker M., et al. The endocannabinoid system controls key epileptogenic circuits in the hippocampus. Neuron 51 (2006) 455-466
22. Nogueiras R., Veyrat-Durebex C., Suchanek P.M., Klein M., Tschöp J., Caldwell C., Woods S.C., Wittmann G., Watanabe M., Liposits Z., et al. Peripheral, but not central, CB1 antagonism provides food intake-independent metabolic benefits in diet-induced obese rats. Diabetes 57 (2008) 2977-2991
23. Osei-Hyiaman D., Liu J., Zhou L., Godlewski G., Harvey-White J., Jeong W.I., Bátkai S., Marsicano G., Lutz B., Buettner C., and Kunos G. Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice. J. Clin. Invest. 118 (2008) 3160-3169
24. Pagotto U., Marsicano G., Cota D., Lutz B., and Pasquali R. The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr. Rev. 27 (2006) 73-100
25. Ravinet Trillou C., Delgorge C., Menet C., Arnone M., and Soubrié P. CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity. Int. J. Obes. Relat. Metab. Disord. 28 (2004) 640-648
26. Scheen A.J. CB1 receptor blockade and its impact on cardiometabolic risk factors: overview of the RIO programme with rimonabant. J. Neuroendocrinol. 20 Suppl 1 (2008) 139-146
27. Tedesco L., Valerio A., Cervino C., Cardile A., Pagano C., Vettor R., Pasquali R., Carruba M.O., Marsicano G., Lutz B., et al. Cannabinoid type 1 receptor blockade promotes mitochondrial biogenesis through endothelial nitric oxide synthase expression in white adipocytes. Diabetes 57 (2008) 2028-2036
28. Thackeray J.T., Beanlands R.S., and Dasilva J.N. Presence of specific 11C-meta-Hydroxyephedrine retention in heart, lung, pancreas, and brown adipose tissue. J. Nucl. Med. 48 (2007) 1733-1740
29. Tsou K., Brown S., Sañudo-Peña M.C., Mackie K., and Walker J.M. Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience 83 (1998) 393-411
30. Verty A.N., Allen A.M., and Oldfield B.J. The effects of rimonabant on brown adipose tissue in rat: implications for energy expenditure. Obesity (Silver Spring) 17 (2009) 254-261
31. Wager-Miller J., Westenbroek R., and Mackie K. Dimerization of G protein-coupled receptors: CB1 cannabinoid receptors as an example. Chem. Phys. Lipids 121 (2002) 83-89
32. Wittmann G., Deli L., Kalló I., Hrabovszky E., Watanabe M., Liposits Z., and Fekete C. Distribution of type 1 cannabinoid receptor (CB1)-immunoreactive axons in the mouse hypothalamus. J. Comp. Neurol. 503 (2007) 270-279